Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06512259

AlloMend Acellular Dermal Matrix Allograft in Pre-Pectoral Breast Reconstruction

This is a single-center, retrospective study which will be used to describe and evaluate the effectiveness of AlloMend® Acellular Dermal Matrix allograft for patients that have undergone Pre-Pectoral Breast Reconstruction surgery following a single or double mastectomy.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

Female

Study type

Observational

Primary location

Alan H. Chen Surgical Associates, PC

Joliet, Illinois, 60435, United States

Location status: Recruiting

Location contact

Alan Chen, MD

PRINCIPAL_INVESTIGATOR

Ashtyn N Janovyak, MS, PA-C

CONTACT

[email protected]

Ashtyn N Janovyak, MS, PA-C

SUB_INVESTIGATOR

About this study

AlloMend® Acellular Dermal Matrix is a sterile, ready to use, human-derived acellular dermal matrix (ADM) allograft that can be used in a number of reconstructive and other surgical procedures. It is made from donated human full-thickness skin. After the epidermal and hypodermal layers are removed, the tissue is treated by a proprietary cleansing process.

AlloMend® is intended to be used in conjunction with a breast implant or tissue expander to stabilize implant position and minimize implant loss during post-single or double mastectomy, unilateral or bilateral pre-pectoral breast reconstruction in women 18 years of age or older. AlloMend® may be used in either one-stage (direct-to-implant) or two-stage (expander-to-implant) procedures.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Patients must meet the following inclusion criteria to participate in this study:

  • Diagnosed by a physician and required a single or double mastectomy followed by Pre-Pectoral Breast Reconstruction surgery with the use of AlloMend® Acellular Dermal Matrix allograft;
  • Surgical intervention using AlloMend® Acellular Dermal Matrix allograft was used;
  • Has completed or will complete the anticipated clinically indicated follow-up visits at 2 weeks, 6 weeks, 3 months, and 6 months post-surgical intervention.

Exclusion criteria

Patients must not meet any of the following criteria to be considered for this clinical trial:

  • Did not utilize AlloMend® Acellular Dermal Matrix allograft during pre-pectoral breast reconstruction
  • Did not have post-operative evaluations at the clinical site.

Treatment and study plan

AlloMend® Acellular Dermal Matrix allograft

Other

AlloSource, a non-profit supplier of allografts and one of the nation's leading tissue banks, introduced AlloMend® Acellular Dermal Matrix allograft to bring the benefits of regenerative medicine to more patients. cellular allograft matrices, unlike synthetic materials or xenografts, are recognized as human tissue by the body for graft incorporation by the recipient, minimizing the risk of inflammation or rejection. AlloMend® Acellular Dermal Matrix allograft has been shown to incorporate into the surgical site and demonstrates blood vessel infiltration.

Primary outcomes

  1. Descriptive Data Collection

    Time frame: Up to 6- months post-operatively

    The primary objective is to obtain descriptive data and surgical intervention and post operative surgical outcome data on AlloMend® Acellular Dermal Matrix allograft for patients that have undergone Pre-Pectoral Breast Reconstruction surgery following a single or double mastectomy.

Secondary outcomes

  1. Physical Function and Quality of Life

    Time frame: Up to 6- months post-operatively

    Secondary Objectives will identify changes in physical function and quality of life as assessed for a period of 6-months post-operatively.

Other outcomes

  1. Qualitative Data

    Time frame: Up to 6- months post-operatively

    Qualitative data such as return to wound healing, pain, discomfort, physicial deformity, and revision surgeries will also be collected.

Study contacts

Contact information is provided by the study sponsor or research team.

Elizabeth Esterl, DNP, MS, RN

CONTACT

[email protected]

7207326231

Paige McHenry, MS, ATC, CCRA

CONTACT

[email protected]

2154997062

Sponsors and collaborators

Lead sponsor

AlloSource

Industry

Registry information

Official study title

A Retrospective Study To Evaluate The Safety And Effectiveness Of AlloMend® Acellular Dermal Matrix Used In Post Mastectomy Pre-Pectoral Breast Reconstruction And Followed For Up To 6-Months Post-Operatively.

Important dates

Study start
2023
Primary completion
2026
Study completion
2026
First posted
Jul 22, 2024
Registry last updated
Nov 21, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.